These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
913 related articles for article (PubMed ID: 23870670)
1. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670 [TBL] [Abstract][Full Text] [Related]
2. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Bowen T; Greenbaum J; Charbonneau Y; Hebert J; Filderman R; Sussman G; Del Carpio J; Gold M; Keith P; Moote W; Cecchetto S; Cecchetto O; Sharp D; Broutin O; André C Ann Allergy Asthma Immunol; 2004 Nov; 93(5):425-30. PubMed ID: 15562880 [TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030 [TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. Creticos PS; Maloney J; Bernstein DI; Casale T; Kaur A; Fisher R; Liu N; Murphy K; Nékám K; Nolte H J Allergy Clin Immunol; 2013 May; 131(5):1342-9.e6. PubMed ID: 23622121 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Nolte H; Hébert J; Berman G; Gawchik S; White M; Kaur A; Liu N; Lumry W; Maloney J Ann Allergy Asthma Immunol; 2013 Jun; 110(6):450-456.e4. PubMed ID: 23706715 [TBL] [Abstract][Full Text] [Related]
6. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Nayak AS; Atiee GJ; Dige E; Maloney J; Nolte H Allergy Asthma Proc; 2012; 33(5):404-10. PubMed ID: 23026182 [TBL] [Abstract][Full Text] [Related]
7. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U; Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Frew AJ; Powell RJ; Corrigan CJ; Durham SR; J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133 [TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. Colás C; Monzón S; Venturini M; Lezaun A J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938 [TBL] [Abstract][Full Text] [Related]
19. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet. Nelson H; Lehmann L; Blaiss MS Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864 [TBL] [Abstract][Full Text] [Related]
20. IgE reactivity patterns in patients with allergic rhinoconjunctivitis to ragweed and mugwort pollens. Canis M; Becker S; Gröger M; Kramer MF Am J Rhinol Allergy; 2012; 26(1):31-5. PubMed ID: 22391077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]